Sequana Medical, a leader in innovative medical devices, has announced the successful implantation of its alfapump® device at Mount Sinai Hospital in New York City. This marks a significant milestone as it is the first commercial implantation of the alfapump® in the United States. The procedure took place on November 24, 2025, and represents a pivotal moment for the company as it seeks to expand its presence in the U.S. market.
The alfapump® is designed to automatically remove excess fluid from patients suffering from conditions such as liver cirrhosis and heart failure. By providing a continuous drainage solution, the device aims to improve patient quality of life while reducing the need for frequent hospital visits. The technology has already proven effective in European markets, and its introduction in the U.S. is anticipated to greatly benefit numerous patients.
Dr. Michael O’Reilly, the lead surgeon for the procedure at Mount Sinai, expressed enthusiasm about the device’s potential impact. “The alfapump® represents a major advancement in the management of fluid overload,” he stated. “We are excited to be the first in the U.S. to offer this innovative solution to our patients.”
The implantation at Mount Sinai is part of a larger strategy by Sequana Medical to penetrate the U.S. healthcare sector, which is known for its extensive resources and advanced medical technology. This step is crucial for the company as it seeks to establish partnerships with healthcare providers across the country.
In Europe, the alfapump® has gained recognition for its ability to enhance patient autonomy and comfort. The device allows patients to manage their conditions more effectively, reducing the burden on healthcare systems and improving overall treatment outcomes. The successful launch in the U.S. is expected to generate significant interest from both healthcare professionals and patients alike.
Sequana Medical’s Chief Executive Officer, John O’Dea, highlighted the importance of this milestone. “We believe that the alfapump® will transform the way fluid management is approached in patients with chronic conditions. This implantation is just the beginning of our journey in the U.S.,” he remarked.
Looking ahead, Sequana Medical plans to conduct further clinical studies to validate the alfapump®’s effectiveness and safety within the U.S. population. The company aims to collaborate with leading hospitals and healthcare institutions to ensure that this innovative technology reaches those who need it most.
As the U.S. healthcare landscape continues to evolve, the successful integration of the alfapump® may set a new standard for treating fluid overload conditions. With its first implantation at Mount Sinai, Sequana Medical is poised to make a lasting impact on patient care and medical practices in the United States.
